BidaskClub upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a hold rating to a buy rating in a research report report published on Thursday, BidAskClub reports.

A number of other equities analysts have also recently issued reports on CPRX. Zacks Investment Research cut shares of HENGAN INTL GRP/ADR from a strong-buy rating to a hold rating in a report on Tuesday, May 21st. ValuEngine cut Valero Energy from a hold rating to a sell rating in a report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed a buy rating and set a $15.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright set a $25.00 price target on Onconova Therapeutics and gave the company a buy rating in a report on Tuesday, May 14th. Seven investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus target price of $7.35.

Shares of NASDAQ CPRX opened at $4.07 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.08 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $3.70. Catalyst Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.16. The company has a market capitalization of $418.62 million, a PE ratio of -12.33 and a beta of 2.60.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last issued its earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.12. The business had revenue of $12.45 million during the quarter, compared to the consensus estimate of $2.40 million. During the same period in the prior year, the business earned ($0.06) EPS. On average, research analysts anticipate that Catalyst Pharmaceuticals will post 0.11 earnings per share for the current year.

In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany purchased 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were bought at an average price of $3.23 per share, with a total value of $80,750.00. Following the completion of the acquisition, the chief executive officer now owns 4,762,693 shares in the company, valued at approximately $15,383,498.39. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $28,000. Paloma Partners Management Co acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $30,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Catalyst Pharmaceuticals by 291.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 20,297 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Catalyst Pharmaceuticals by 18.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 5,688 shares during the period. Finally, Biltmore Capital Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $79,000. 59.79% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

Featured Article: Trading Ex-Dividend Strategy

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.